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Abstract
Background. Intravenous (i.v.) iron sucrose similar (ISS)
preparations are available but clinical comparisons with the
originator iron sucrose (IS) are lacking.
Methods. The impact of switching from IS to ISS on
anaemia and iron parameters was assessed in a sequential
observational study comparing two periods of 27 weeks
each in 75 stable haemodialysis (HD) patients receiving
i.v. iron weekly and an i.v. erythropoiesis-stimulating agent
(ESA) once every 2 weeks. Patients received IS in the ﬁrst
period (P1) and ISS in the second period (P2).
Results. Mean haemoglobin value was 11.78 6 0.99 g/dL
during P1 and 11.48 6 0.98 g/dL during P2 (P ¼ 0.01).
Mean serum ferritin was similar for both treatment periods
(P1, 534 6 328 lg/L; P2, 495 6 280 lg/L, P ¼ 0.25)
but mean TSAT during P1 (49.3 6 10.9%) was signiﬁ-
cantly higher than during P2 (24.5 6 9.4%, P <0.0001).
The mean dose of i.v. iron per patient per week was
45.58 6 32.55 mg in P1 and 61.36 6 30.98 mg in P2
(134.6%), while the mean ESA dose was 0.58 6 0.52
and 0.66 6 0.64 lg/kg/week, respectively (113.8%).
Total mean anaemia drug costs increased in P2 by 11.9%
compared to P1.
Conclusions. The switch from the originator IS to an ISS
preparation led to destabilization of a well-controlled
population of HD patients and incurred an increase in total
anaemia drug costs. Prospective comparative clinical
studies are required to prove that ISS are as efﬁcacious
and safe as the originator i.v. IS.
Keywords: anaemia; cost analysis; haemodialysis; intravenous iron; iron
sucrose
Introduction
Anaemia is a common comorbidity in chronic kidney
disease (CKD). Its prevalence rises as renal function dete-
riorates, and it is estimated that up to 70% of patients
are anaemic at the time of starting dialysis [1, 2]. Iron
deﬁciency is an important contributor to renal anaemia,
particularly in haemodialysis (HD) patients as a result
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3262of chronic dialysis-related blood loss and increased iron
demand due to use of erythropoiesis-stimulating agents
(ESA) [2]. Accordingly, intravenous (i.v.) iron supplemen-
tation is an important component in the therapeutic
armamentarium for the management of anaemia in HD
patients [3–5].
There are a number of iron carbohydrate compounds
available on the market and among these compounds iron
sucrose (IS) complex has a favourable safety proﬁle when
administered i.v. [6] as outlined in the European Best Prac-
tice Guidelines [3]. Iron carbohydrates such as IS
are complex macromolecules, and their physico-chemical
and biological properties are closely dependent on the man-
ufacturing process such that subtle structural modiﬁcations
may affect the stability of the preparation [7, 8]. Stability is
of paramount importance, since weakly bound iron may
dissociate too rapidly and catalyse the generation of reac-
tive oxygen species [7–10] that in turn induce oxidative
stress and inﬂammation. Potentially, an unstable iron com-
plex could have safety and efﬁcacy implications, especially
in chronically ill individuals such as HD patients in whom
dialysis and comorbidities already confer an increased bur-
den of oxidative stress and inﬂammation [11, 12].
Several iron sucrose similar (ISS) preparations have
been introduced for the treatment of iron deﬁciency anae-
mia in a number of countries worldwide [7, 11, 13]o nt h e
basis that they can be considered therapeutically equiv-
alent to the originator i.v. IS (Vifor France SA; manufac-
tured by Vifor International Inc., St. Gallen, Switzerland).
However, recent analytical tests and studies in rat models
have demonstrated differences between ISS preparations
and the originator IS in terms of physico-chemical structure
and their effect on inﬂammatory, haemodynamic and func-
tional markers [7, 13]. To our knowledge, no head-to-head
clinical study has yet compared ISS and IS in a patient
population.
At the Centre Suzanne Levy, Paris, IS was used to cor-
rect iron deﬁciency anaemia in HD patients for 6 years prior
to June 2009 at which point the centre switched to the ISS
(Mylan SAS, Saint Priest, France manufactured by Help
SA Pharmaceuticals, Athens, Greece) due to economic
reasons. An observational retrospective and prospective
analysis was undertaken to evaluate the impact of the
switch from the originator IS to the ISS on haemoglobin
(Hb) levels, iron parameters and dosing requirements for
i.v. iron and ESA.
Materials and methods
Study design
This was an observational, non-interventional, single-centre single-cohort
study. The study compared two time periods of 27 weeks each: Period 1
(P1; 1 December 2008 to 7 June 2009) during which patients received IS
and Period 2 (P2; 29 June 2009 to 3 January 2010) during which patients
received the ISS. Data for 3 weeks in June 2009 were excluded as both
medications were simultaneously available at the centre. The medical
management of the patients did not otherwise change during the study
period except for the switch from IS to ISS. The study was initiated in
September 2009 in response to concerns about Hb levels following intro-
ductionof theISS. Data upto thispoint wereobtained retrospectivelyfrom
the patients’ medical records; subsequent data were collected prospec-
tively. As an observationalstudy, it did not requireapproval of the relevant
Ethics Committee according to French regulations.
Objectives
The primary objective was to compare the impact of the switch from IS
to the ISS on Hb levels and iron parameters. Secondary objectives were to
describe the level of consumption of i.v. iron and ESA drugs and to
estimate anaemia drug expenditure for the two treatment periods.
Patients
Patients undergoing chronic HD (three times a week) at the centre were
included in the analysis if they underwent at least 60 dialysis sessions
during both periods (a lower limit was allowed for patients attending for
HD twice a week) and at least one prescription of i.v. iron duringthe study.
IS (5-mL ampoules with 100 mg iron) or ISS (5-mL ampoules with 100
mg iron) were injected i.v. once a week at a dose of 25–100 mg iron. ESA
(darbepoetin-a) was injected i.v. once every 2 weeks.
Evaluation
Hb, serum calcium, serum phosphorus, leucocytes, platelets, neutrophils
and urea (before the HD session) were assessed every 2 weeks. Transferrin
saturation (TSAT), serum ferritin, alkaline phosphatase, parathyroid hor-
mone (PTH), 25-OH vitamin D, albumin, urea (after the HD session),
adequacy of dialysis (Kt/V), C-reactive protein (CRP), ﬁbrinogen,
gamma-glutamyl transpeptidase (c-GT), aspartate aminotransferase
(AST), alanine aminotransferase (ALT) and total bilirubin were measured
every 3 months. All adverse events were reported according to applicable
regulations and adverse events resulting in hospitalization were recorded.
Statistical analysis
Between-period comparisons were performed using the paired Student’s
t-test and the paired Wilcoxon test for continuous data, and the McNemar
test (v
2) for qualitative data. A hierarchical (mixed-effects) model [14] was
used to estimate trends in the mean values of Hb for the following three
time periods:
Table 1. Baseline demographic and clinical characteristics (n ¼ 75)
a
Age, years 63.4 6 15.2
Female/male 31%/69%
Duration of HD, months 55.0 6 53.1
Primary renal disease, n (%)
Diabetes 28 (37.3)
Glomerulonephritis 18 (24.0)
Hypertension 13 (17.3)
Other nephropathies 16 (21.3)
aContinuous variables are shown as mean 6 SD.
Fig. 1. Mean haemoglobin levels over time by treatment period
(grams per deciliter).
Interchangeability of iron sucrose 3263(1) baseline, i.e. the period of IS administration (Hb measurements 1–14),
(2) immediately before and after the switch to ISS (between Hb measure-
ments 14 and 15) and
(3) after switch to ISS (measurements 15–28).
To carry out the analysis, splines with three knots at 14, 15 and 28
weeks were used, which deﬁned three slopes corresponding, respectively,
to the trends in Hb levels for the three periods deﬁned. Hence, the estimate
of the ﬁrst spline in the mixed-effects model corresponds to change in Hb
during the baseline period; similarly, the estimate of the second spline
represents the change in Hb values immediately following the introduction
of the new product and the estimate of the third spline represents the
change in Hb values thereafter (with increases in dose of i.v. iron and
ESA).
Both random-intercept and random-coefﬁcients (random intercept and
slopes) models were ﬁtted to account for the repeated measures of Hb
within each patient.
The cost of i.v. iron medications and ESA over time was calculated for
both periods. The unit cost of i.v. iron (public price) was 12.98V/ampoule
(100 mg iron) for IS and 10.20V/ampoule (100 mg iron) for ISS. The cost
of darbepoetin-a at the centre was 1.47V/lg. Results were extrapolated to
obtain a yearly incremental cost per patient by multiplying the daily cost
per patient by 365. A national drug expenditure impact was estimated
based on the assumption that the total French dialysis population (esti-
mated to be 37 000 patients in January 2009 [15]) would be switched from
IS to the ISS. This extrapolation is only indicative as unit cost estimates
were centre speciﬁc, especially concerning darbepoetin-a.
Results
Patient population
Of 120 patients receiving dialysis at the centre, 75 patients
were eligible for inclusion in the analysis. The demo-
graphics and clinical proﬁle of the population were typical
for adult recipients of chronic HD (Table 1)[ 16]. The mean
number of dialysis sessions per patient performed was sim-
ilar during P1 (75.1   5.1) and P2 (75.1   6.3, P ¼ 0.97).
Efﬁcacy
Haemoglobin. Mean Hb levels throughout the study are
presented in Figure 1. Values during IS treatment were
statistically signiﬁcantly higher than during use of the
ISS (P1, 11.78   0.99 g/dL; P2, 11.48   0.98 g/dL, P ¼
0.01). The difference was more pronounced when Hb
values during P1 were compared to the ﬁrst 3 months of
P2 (11.78   0.99 g/dL and 11.39   1.12 g/dL, respec-
tively, P ¼ 0.005 versus P1). Mean Hb levels were similar
during the ﬁrst and last 3 months of P2 (11.39   1.12 g/dL
and 11.57   1.09 g/dL, respectively, P ¼ 0.15).
Themixedmodel(randomintercept)analysisdemonstra-
ted that Hb levels were stable during the IS treatment period
as the ﬁrst slope (Hb measurements 1–14) was not statisti-
cally different from 0 (P ¼ 0.105). The second slope (Hb
measurements 14–15) was statistically different from
0( P<0.0001) with a coefﬁcient of  0.4 g/dL per two
observations for the period, i.e. switch from IS to the ISS
was associated with a signiﬁcant decrease in mean Hb val-
ues of 0.4 g/dL (95% conﬁdence interval  0.55 to  0.23).
The third slope (Hb measurements 15–28) was also statisti-
cally different from 0 (P ¼ 0.001) with an increase of 0.026
per two observations (0.34 g/dL). Results of the mixed
model (random-intercept and slopes) also showed the sec-
ond slope to be statistically different from 0 (P ¼ 0.002)
with a coefﬁcient of  0.40 g/dL, but the third slope did not
reach statistical signiﬁcance (P ¼ 0.167), although the trend
was similar (0.020 per two observations).
The proportion of patients who had at least one Hb value
within the target range (11.5–12.0 g/dL) was 85% during
P1 and 79% during P2 (P ¼ 0.25). The mean number of
days spent outside the target Hb range was 78 days per
patient (cumulative 5880 days) during P1 compared to a
mean of 99 days per patient (cumulative 7470 days) during
P2 (P ¼ 0.02) (Figure 2).
Iron parameters. Mean serum ferritin was similar
between the treatment periods (P1, 533.8   327.5 lg/L;
P2, 494.5   279.9 lg/L, P ¼ 0.25) but was statistically
signiﬁcantly higher in P1 versus the ﬁrst evaluation per-
formed in P2 (September) (457.7   290.4 lg/L, P ¼ 0.04)
(Table 2). Mean TSAT during P1 (49.3   10.9%) was
statistically signiﬁcantly higher than during P2 overall
(24.5   9.4%, P < 0.0001) or Month 3 of P2 (23.3  
10.2%, P < 0.0001) (Table 2).
Intravenous iron consumption. The mean dose of i.v.
iron per patient was 1231   879 mg in P1 and 1657  
866 mg in P2 (P ¼ 0.001), representing a 34.6% increase in
i.v. iron during P2 versus P1. Corresponding values for i.v.
iron per patient per week were 61.36   30.98 mg in P2 and
45.58   32.55 mg in P1 (P ¼ 0.001), and the cumulative
dose for the total study population was 92 300 mg in P1
versus 124 250 mg in P2.
ESA consumption. The mean dose of ESA per patient
was 980   756 and 1103   908 lg, respectively, during
Table 2. Serum ferritin and TSAT during Period 1 and at Month 3 of
Period 2 (September 2009)
Period 1 (n ¼ 75)
Month 3, Period 2
(n ¼ 75) P-value
Serum ferritin (lg/L)
Mean 6 SD 533.8 6 327.5 457.7 6 290.4 0.04
Median (range) 551.2 (38.3–1051.5) 432.1 (13.7–1541.1)
TSAT (%)
Mean 6 SD 49.3 6 10.9 23.3 6 10.2 <0.0001
Median (range) 47.7 (32.0–80.0) 23.0 (5.0–44.0)
Fig. 2. Mean number of days spent outside the haemoglobin target range
(11.5–12.0 g/dL) by treatment period.
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mean dose according to body weight was 0.58   0.52 lg/
kg/week in P1 and 0.66   0.64 lg/kg/week during P2 (P ¼
0.13) representing a 13.8% increase. The cumulative dose
of ESA in P1 was 73 510 lg for the total study population
and 82 750 lgi nP 2( 112.6%).
The mean fortnightly i.v. iron dose and concomitant
ESA dose throughout the study versus achieved Hb levels
are shown in Figure 3.
Economic impact. The cumulative cost of i.v. iron was
11 981V during P1 and 12 674V during P2. For ESA,
the cumulative cost was 108 060V during P1 and
121 643V during P2. The total cost from the health
care provider’s perspective (including both i.v. iron and
ESA) was 120 040V and 134 316V during P1 and P2,
respectively, a difference of 14 276V (111.9% increase)
(Figure 4). The incremental cost of switching from IS to the
ISS for 1 year was estimated to be about 368V per patient.
Safety
Mean values for serum phosphorus, Ca 3 P, 25-OH vitamin
D and urea decreased signiﬁcantly, and total bilirubin in-
creased signiﬁcantly, during P2 compared to P1 (Table 3).
There were no signiﬁcant differences between the two treat-
ment periods regarding serum calcium, PTH, CRP, albumin,
ﬁbrinogen, c-GT, alkaline phosphatase, ALT, AST, leuco-
cytes, platelets, neutrophils or Kt/V. Mean CRP showed a
non-signiﬁcant increase from P1 [6.3   6.9 mg/L (median
3.3 mg/L)] to the last 3 months of P2 [9.1   14.6(median3.0
mg/L), P ¼ 0.09] in 70 patients. A further CRP measurement
was performed in January 2010 on the last day of use of ISS
and the mean value was 13.7 mg/L.
No adverse events were observed in relation to the study
drugs during the study and no hospitalization related to i.v.
iron supplementation occurred. Adverse events that
resulted in hospitalization were considered to be related
to the pre-existing conditions including CKD. There was
no signiﬁcant difference concerning the proportion of hos-
pitalized patients between P1 [12/75 (16.0%)] and P2
[11/75 (14.7%), P ¼ 0.78]. Five patients were hospitalized
twice during P1 and P2. Seven patients were hospitalized
during P1 only and six patients were hospitalized during
P2 only. The cumulative length of hospital stay was 191
days during P1 and 107 days during P2. The mean length
of stay per hospitalized patient was similar during P1 and
P2 (10.6 days versus 5.9 days, respectively, P ¼ 0.461,
Wilcoxon test on paired data).
Discussion
This is the ﬁrst study to evaluate the clinical impact of
switching from the originator i.v. IS to an ISS. In this
Fig. 3. Mean fortnightly dose of i.v. iron (milligrams) and ESA [darbepoetin-a (micrograms)] versus achieved haemoglobin levels (grams per deciliter).
Fig. 4. Anaemia drug expenditure.
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associated with a signiﬁcant reduction in Hb level and
reduced iron indices despite an increase in i.v. iron dose,
ESA dose and an overall increase in drug expenditure.
The decrease in Hb level during ISS therapy coupled
with a shorter proportion of time spent within the Hb target
range may have clinical implications for this high-risk pop-
ulation. Cardiac complications and impaired quality of life
are well-documented consequences of poor anaemia con-
trol in the CKD and HD populations [4, 5, 17, 18]. More-
over, there was a marked and signiﬁcant increase in the
dose of iron that was required after the switch, accompa-
nied by a numerical increase in ESA dose. Long-term ex-
posure to higher doses of drugs such as i.v. iron and
ESA increase the risk of toxicity [19] and are associated
with increased oxidative stress and inﬂammation [9]
that can exacerbate the existing pro-oxidant effects of co-
morbidities, uraemia and the dialysis procedure [20].
The marked reduction in Hb that was already apparent at
the start of the ISS treatment period reﬂects the immediate
effect of switching i.v. iron preparation. Towards the end
of the 20-day interval in June 2009 when both the IS and
ISS preparations were used, stock levels available at the
centre suggest that two-thirds of patients were likely to
have received ISS. Intravenous iron treatment exerts a rapid
effect, with the administered iron being incorporated into
red blood cells within days [21], such that the switch to ISS
appears to have quickly led to lower Hb levels. We are not
aware of any other factors that could have accounted for
the change in Hb level from the end of Period 1 to the start
of Period 2 in this single cohort of patients for whom man-
agement was otherwise consistent throughout the study.
The discrepancy in Hb levels seen during administration
of IS and ISS may be due to variations in the stability of the
complexes and the bioavailability of iron from the two
preparations. It can be hypothesized that the kinetics of
iron dissociation differ between the two complexes, affect-
ing the pattern of iron distribution and storage. This is
supported by the halving of mean TSAT level during ISS
therapy compared to the original IS, which occurred despite
regular application of i.v. iron and an increased iron dose.
The reduction in TSAT indicates that a lower proportion
of iron was available for erythropoiesis. If iron is not uti-
lized for erythropoiesis, it may be sequestered in other
compartments in the body from which it is not available
for erythropoiesis and could potentially cause harmful ef-
fects, which would be consistent with the increased levels
of bilirubin and CRP observed during the ISS treatment
period. Two recent studies found signiﬁcant iron deposits
in the liver, kidney and heart tissue of rats following ad-
ministration of ISS preparations compared to the originator
i.v. IS [7, 13]. Moreover, proinﬂammatory cytokine levels
such as interleukin-6 and tumor necrosis factor-a were
higher in the liver, heart and kidney tissues of rats treated
with ISS [7, 13], possibly due to iron accumulation in the
wrong compartment. These results may indicate reduced
stability of ISS complexes and increased oxidative stress
and inﬂammation secondary to the presence of weakly
bound iron [7, 8, 13]. Further studies are required to exam-
ine this issue in more detail.
Both preparations showed a good safety proﬁle, with
no adverse events related to either study drug being ob-
served. A longer term prospective controlled study is re-
quired to evaluate the impact of the ISS on clinical safety
parameters and to investigate the interchangeability with
the originator IS.
The lower levels of TSAT and serum ferritin during ISS
therapy, particularly during the ﬁrst 3 months after switch,
are likely to have contributed to increased ESA dosing,
with economic implications. Besarab et al. [22] demonstra-
ted that maintenance of TSAT between 30 and 50%
through maintenance i.v. iron administration improves
anaemia and reduces ESA dose requirements. Economi-
cally, in contrast to the expected reduction in drug cost
due to the purchase of the less expensive ISS ( 21%), total
anaemia drug expenditure increased by 11.9% due to
higher dosing of ESA and i.v. iron. This resulted in an
absolute drug expenditure increase of ~368V/year per
Table 3. Laboratory values with statistically signiﬁcant differences between Periods 1 and 2
(n ¼ 75)
Period 1 Period 2 P-value
Serum phosphorus (mmol/L)
Mean 6 SD 1.8 6 0.5 1.6 6 0.4 0.0002
Median (range) 1.7 (0.6–3.1) 1.6 (0.8–2.3)
Ca 3 P
Mean 6 SD 4.0 6 1.1 3.7 6 0.8 <0.0001
Median (range) 4.0 (1.4–6.4) 3.7 (1.8–5.1)
25-OH vitamin D (ng/mL)
Mean 6 SD 20.0 6 9.2 16.7 6 9.39 0.008
Median (range) 18.0 (5–45.5) 16.0 (0–43)
Urea before (mmol/L)
Mean 6 SD 22.6 6 6.1 20.6 6 4.6 <0.0001
Median (range) 21.8 (11.9–42.7) 20.7 (12.2–37.7)
Urea after (mmol/L)
Mean 6 SD 6.6 6 2.7 5.8 6 1.9 0.002
Median (range) 6.3 (2.2–18.1) 5.6 (2.1–11.1)
Total bilirubin (lmol/L)
Mean 6 SD 7.7 6 1.8 8.8 6 2.3 0.001
Median (range) 7.7 (4.3–13.3) 8.5 (5.0–18.0)
3266 J. Rottembourg et al.patient, equivalent to ~13.6 million V/year if extrapolated
to the French HD population.
In conclusion, the switch from the originator IS to an ISS
preparation led to destabilization of a well-controlled
population of HD patients, with a signiﬁcant decrease of
Hb levels and iron indices coupled with a need to increase
anaemia drug consumption. The economic rationale for
switch to a less expensive iron preparation was negated
by the increase in total drug costs. Prospective compara-
tive studies are required to conﬁrm the efﬁcacy and
safety of ISS and their interchangeability with the orig-
inator i.v. IS.
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